Magaña-Zamora L, Chiquete E, Campos-González ID, Cantú-Leal R, Ibarra-Bravo O, Punzo-Bravo G, Rojas-Flores I

Language: Spanish
References: 36
Page: 78-85
PDF size: 238.60 Kb.

ABSTRACT

Introduction: Multiple sclerosis (MS) has not been completely studied in different regions of Mexico. The lack of information could be a barrier for the correct identification and management of patients living with MS. Objective: To describe factors associated with MS and its functional outcome in a Mexican population. Material and methods: A case-control studied was performed. From June 2008 to June 2010 cases with MS were registered from different communities of the State of Michoacan. An equal number of age-and-sex paired subjects without known neurologic disease comprised the control group. All were investigated for risk factors. Results: A total of 75 patients met MS diagnostic criteria: mean age 3.6 years, female-tomale ratio of 2:1, 77% from Morelia City, 81% with relapsing-remitting MS. In univariate analysis, as compared with controls, patients with MS were more educated, and had a higher frequency of family history for MS and of autoimmune diseases. However, in the multivariate analysis only the family history of autoimmune disease was significantly associated with MS risk. The most frequent treatment for MS was interferon beta (50%), combined immunosuppression (36%), steroids alone (8%), and azathioprine (1%). Nonetheless, 50% of MS patients declared using complementary therapies. In a Cox proportional hazards model, only the type of MS was a prognosticator of a score in the Expanded Disability Status Scale › 4, during a mean disease duration of 5 years (progressive forms of MS, RR: 7.29; IC del 95%: 2.51-21.19). Conclusion: In this study the most important epidemiological risk factor for MS was the family history of autoimmunity. On the other hand, the type of MS was the main determinant of functional outcome.

REFERENCES

1. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.

2. Hassan-Smith G, Douglas MR. Management and prognosis of multiple sclerosis. Br J Hosp Med (Lond) 2011; 72: M174-6.

3. Flores-Rivera JJ. Fingolimod: Una novedosa terapia, modulador de los receptores de esfingosina para las formas recurrentes de esclerosis múltiple. Rev Mex Neuroci 2010; 11: 234-9.

4. Alter M, Olivares L. Multiple sclerosis in Mexico. An epidemiologic study. Arch Neurol 1970; 23: 451-9.

5. Rodríguez GA, Sotelo MJ. [Multiple sclerosis in Mexico]. Salud Publica Mex 1981; 23: 451-6.

6. Gonzalez O, Sotelo J. Is the frequency of multiple sclerosis increasing in Mexico? J Neurol Neurosurg Psychiatry 1995; 59: 528-30.

7. Corona T, Rodrigues JL, Otero E, Stopp L. Multiple sclerosis in Mexico: hospital cases at the National Institute of Neurology and Neurosurgery, Mexico City. Neurologia 1996; 11: 170-3.

8. De la Maza M, García J, Bernal J, Fuentes M. [A review of the epidemiology of multiple sclerosis in Mexico]. Rev Neurol 2000; 31: 494-5.

9. Velázquez-Quintana M, Macías-Islas MA, Rivera-Olmos V, Lozano-Zárate J. [Multiple sclerosis in Mexico: a multicentre study]. Rev Neurol 2003; 36: 1019-22.

10. Cordova J, Vargas S, Sotelo J. Western and Asian features of multiple sclerosis in Mexican Mestizos. Clin Neurol Neurosurg 2007; 109: 146-51.

11. Aguirre-Cruz L, Flores-Rivera J, De La Cruz-Aguilera DL, Rangel-López E, Corona T. Multiple sclerosis in Caucasians and Latino Americans. Autoimmunity 2011; 44: 571-5.

12. Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002; 58: 136-8.

13. Warren SA, Svenson LW, Warren KG. Contribution of incidence to increasing prevalence of multiple sclerosis in Alberta, Canada. Mult Scler 2008; 14: 872-9.

14. Gray OM, McDonnell GV, Hawkins SA. Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland. Mult Scler 2008; 14: 880-6.

15. Bentzen J, Flachs EM, Stenager E, Brønnum-Hansen H, Koch-Henriksen N. Prevalence of multiple sclerosis in Denmark 1950-2005. Mult Scler 2010; 16: 520-5.

16. Ahlgren C, Odén A, Lycke J. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler 2011; 17: 901-8.

17. Millefiorini E, Cortese A, Di Rezze S, Barletta G, Bellantonio P, Batocchi AP, Di Battista G, et al. The prevalence of multiple sclerosis in central Italy. Mult Scler 2010; 16: 1432-6.

18. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002; 104: 182-91.

19. Risco J, Maldonado H, Luna L, Osada J, Ruiz P, Juarez A, Vizcarra D. Latitudinal prevalence gradient of multiple sclerosis in Latin America. Mult Scler 2011; 17: 1055-9.

20. Osoegawa M, Kira J, Fukazawa T, Fujihara K, Kikuchi S, Matsui M, et al. Research Committee of Neuroimmunological Diseases. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 2009; 15: 159-73.

21. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58: 840-6.

22. Montalban X, Sastre-Garriga J, Filippi M, Khaleeli Z, Téllez N, Vellinga MM, et al. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Mult Scler 2009; 15: 1459-65.

23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.

24. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology 2009; 73: 1996-2002.

25. Koch M, Kingwell E, Rieckmann P, Tremlett H; UBC MS Clinic Neurologists. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2010; 81: 1039-43.

26. Williamson DM, Marrie RA, Ashley-Koch A, Schiffer R, Trottier J, Wagner L. Design, methodological issues and participation in a multiple sclerosis case-control study. Acta Neurol Scand 2011 [Epub ahead of print].

27. Weinstock-Guttman B, Ramanathan M. Multiple sclerosis in 2011: Advances in therapy, imaging and risk factors in MS. Nat Rev Neurol 2012; 8: 66-8.

28. Ordoñez G, Martinez-Palomo A, Corona T, Pineda B, Flores-Rivera J, Gonzalez A, Chavez-Munguia B, et al. Varicella zoster virus in progressive forms of multiple sclerosis. Clin Neurol Neurosurg 2010; 112: 653-7.

29. Sotelo J, Martínez-Palomo A, Ordoñez G, Pineda B. Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis. Ann Neurol 2008; 63: 303-11.

30. Burgoon MP, Cohrs RJ, Bennett JL, Anderson SW, Ritchie AM, Cepok S, Hemmer B, et al. Varicella zoster virus is not a disease-relevant antigen in multiple sclerosis. Ann Neurol 2009; 65: 474-9.

31. Gilden DH. Is varicella zoster virus really involved in the pathogenesis of multiple sclerosis? Ann Neurol 2008; 63: 269-71.

32. Maya R, Gershwin ME, Shoenfeld Y. Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol 2008; 34: 85-102.

33. Balinska MA. Hepatitis B vaccination and French Society ten years after the suspension of the vaccination campaign: how should we raise infant immunization coverage rates? J Clin Virol 2009; 46: 202-5.

34. DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, Shinefield HR, et al. Vaccine Safety Datalink Research Group, National Immunization Program, Centers for Disease Control and Prevention. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003; 60: 504-9.

35. Jafari N, Hintzen RQ. The association between cigarette smoking and multiple sclerosis. J Neurol Sci 2011; 311: 78-85.

36. Alonso A, Cook SD, Maghzi AH, Divani AA. A case-control study of risk factors for multiple sclerosis in Iran. Mult Scler 2011; 17: 550-5.